BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 19391415)

  • 1. [Therapy of gastric acid-induced illnesses in general practice. The first pantoprazole generic drug has arrived].
    MMW Fortschr Med; 2009 Jan; 151(5):46-7. PubMed ID: 19391415
    [No Abstract]   [Full Text] [Related]  

  • 2. [Analysis of actual costs in long-term therapy of reflux disease. Use of pantoprazole counts].
    MMW Fortschr Med; 2008 Oct; 150(40):52-3. PubMed ID: 18990887
    [No Abstract]   [Full Text] [Related]  

  • 3. [Decreased need for tablets with pantoprazole. PPI: independent study questions savings through use of generic drugs].
    MMW Fortschr Med; 2007 Dec; 149(49-50):58. PubMed ID: 18236985
    [No Abstract]   [Full Text] [Related]  

  • 4. A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands.
    van Hout BA; Klok RM; Brouwers JR; Postma MJ
    Clin Ther; 2003 Feb; 25(2):635-46. PubMed ID: 12749518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [General practitioners' management of gastroesophageal reflux in France in 2005: a pharmacoeconomic study].
    Mouly S; Charlemagne A; Le Jeunne P; Fagnani F
    Presse Med; 2008 Oct; 37(10):1397-406. PubMed ID: 18502602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generics offer pharmacy plans specific benefits.
    Reinke T
    Manag Care; 2010 Feb; 19(2):28-30, 34. PubMed ID: 20550049
    [No Abstract]   [Full Text] [Related]  

  • 7. [Gastroesophageal reflux in the adult: medical-economic aspects of therapeutic strategies].
    Lebrun T; Bouchez M; Allenet B
    Gastroenterol Clin Biol; 1999 Jan; 23(1 Pt 2):S165-75. PubMed ID: 10078445
    [No Abstract]   [Full Text] [Related]  

  • 8. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
    Lucas LM; Gerrity MS; Anderson T
    Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The acid test for formulary policy.
    McCaffrey E
    Bus Health; 1999 Dec; 17(12 Suppl A):19-24. PubMed ID: 10747676
    [No Abstract]   [Full Text] [Related]  

  • 10. [Preparation sanpraz (pantoprazole): experience of application in treatment of gastroesophageal reflux disease and other acid related diseases].
    Sharova EP
    Eksp Klin Gastroenterol; 2008; (6):74-6. PubMed ID: 19334429
    [No Abstract]   [Full Text] [Related]  

  • 11. The treatment of gastroesophageal reflux disease with proton-pump inhibitors and its implications on managed care--pharmacoeconomics and its application to antisecretory drugs: a case study.
    Morreale A
    Manag Care Interface; 2001; Suppl B():28-30; discussion 31-3. PubMed ID: 11569296
    [No Abstract]   [Full Text] [Related]  

  • 12. [Efficacy and tolerability of pantoprazole in the treatment of gastroesophageal reflux disease].
    Gillessen A
    MMW Fortschr Med; 2010 May; 152(18):52. PubMed ID: 20514766
    [No Abstract]   [Full Text] [Related]  

  • 13. [Drug treatment and surgical indications in gastroesophageal reflux].
    PĂ©rez-Manauta J
    Rev Gastroenterol Mex; 2007 Nov; 72 Suppl 2():13-6. PubMed ID: 18277473
    [No Abstract]   [Full Text] [Related]  

  • 14. OTC omeprazole for your heartburn--enormous value-for-money opportunity.
    Curtiss FR
    J Manag Care Pharm; 2004; 10(5):458-60. PubMed ID: 15369431
    [No Abstract]   [Full Text] [Related]  

  • 15. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P; Katz PO; Chen Y; Sostek M
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acid pump inhibitors. The treatment of gastroesophageal reflux.
    Hetzel D
    Aust Fam Physician; 1998 Jun; 27(6):487-91. PubMed ID: 9648315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
    Lim PW; Goh KL
    J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S61-8. PubMed ID: 15324384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
    Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
    Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients.
    Calabrese C; Liguori G; Gabusi V; Gionchetti P; Rizzello F; Straforini G; Brugnera R; Di Febo G
    Aliment Pharmacol Ther; 2008 Jul; 28(2):250-5. PubMed ID: 18485128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness analysis for the treatment of non-erosive reflux disease].
    Habu Y; Fukui Y; Maruno T; Hisatsune H; Kawai K
    Nihon Rinsho; 2007 May; 65(5):951-5. PubMed ID: 17511239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.